Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for chronic liver disease. The company’s lead asset is CRV431, a cyclophilin inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH).
More Hepion Pharmaceuticals content >Investment summary
Recently, Hepion released top-line data from its AMBITION Phase IIa trial with CRV431, a cyclophilins inhibitor, in non-alcoholic steatohepatitis (NASH) patients. All primary safety, tolerability and pharmacokinetics were met and support once-a-day dosing. The company plans to conduct a Phase IIb (ASCEND-NASH) trial this year in NASH patients with fibrosis levels 2 or 3 (F2 or F3). The ASCEND-NASH trial will be significantly larger with 300 patients enrolled. The primary endpoint will be a 1-point reduction in fibrosis score in liver biopsies.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2019A | 0.0 | (7.7) | (7.9) | (341.55) | N/A | N/A |
| 2020A | 0.0 | (17.7) | (17.9) | (185.69) | N/A | N/A |
| 2021E | 0.0 | (27.0) | (27.0) | (35.49) | N/A | N/A |
| 2022E | 0.0 | (28.5) | (28.5) | (35.68) | N/A | N/A |
Content on Hepion Pharmaceuticals
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 102.2 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Robert Foster | CEO |
| John Cavan | FD |